Two ADCs are already on the market, including CD30‐targeted brentuximab vedotin for relapsed Hodgkin's lymphoma and anaplastic large cell lymphoma 16, and Her2‐targeted trastuzumab emtansine for refractory Her2‐expressing breast cancers 17. Here, ERBB2 is linked to breast cancer.